Pre–existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18–30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data - Summary - MDSpire
Advertisement
Pre–existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18–30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data
To investigate whether chronic comorbidities (hypertension, diabetes, dyslipidemia, and obesity) modify the risk of myocarditis or pericarditis following mRNA COVID-19 vaccination in males aged 18–30.
Approach:
Study Design: A case-coverage study using observed-versus-expected (O/E) and disproportionality analyses was conducted on VAERS data.
Data Sources: VAERS data from 2021–2022 were utilized to identify reports of myocarditis and pericarditis in the target population.
Outcome Definition: Reports of myocarditis or pericarditis suspected to be associated with mRNA vaccination were included, with specific eligibility criteria applied.
The study applies disproportionality methods to assess vaccine-related adverse events and finds that common comorbidities do not significantly modify the risk of myocarditis/pericarditis post-vaccination.
The findings indicate that pre-existing comorbid conditions do not appear to increase the risk of myocarditis or pericarditis following mRNA COVID-19 vaccination in young males.
A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
